Vertex Pharmaceuticals' $10 billion acquisition of an endocrinology startup represents the company’s clearest and boldest step toward the upper echelon of the biopharma industry. Long a biotech success in cystic fibrosis, Vertex has been angling …
Source: Endpoints News
